Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure

By afschroeder • September 20, 2025

Green L, Armstrong A, Han G, Jacobson A. Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure. Dermatol Ther (Heidelb). 2025 Sep 19. doi: 10.1007/s13555-025-01533-9. Epub ahead of print. PMID: 40971026.

Tags: Biologic failure, Dermatology, ixekizumab, Publications, Quality of Life, Refractory, secukinumab, Therapy switching, tnf inhibitor

Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]

Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis

Yan MJ, Jiang YC, Wongvibulsin S, Chen ST. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis. JID Innov. 2025 Nov 17;6(2):100435.[...]

Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical Board

Blauvelt A, Prussick R, Merola JF, Shahriari M, Cather J, Eakin GS, McCormick Howard L, Lebwohl MG, Armstrong AW, Duffin KC. Clarifying Psoriasis Disease Severity:[...]